Axsome Therapeutics Launches Phase 3 Trial for Smoking Cessation Drug AXS-05
Event summary
- Axsome Therapeutics initiated the SUMMIT Phase 3 trial for AXS-05 in smoking cessation on August 31, 2026.
- The trial is a randomized, double-blind, active- and placebo-controlled study with a primary endpoint of smoking abstinence at 12 weeks.
- AXS-05 is a novel oral investigational drug with a patent estate extending to at least 2043.
- The drug is already approved for major depressive disorder and agitation associated with Alzheimer’s disease.
The big picture
Axsome Therapeutics is expanding its portfolio beyond approved indications for major depressive disorder and Alzheimer’s-related agitation. The SUMMIT trial represents a strategic pivot into the smoking cessation market, addressing a significant unmet need with a novel mechanism of action. The success of this trial could position AXS-05 as a key player in a market with substantial health-economic implications.
What we're watching
- Clinical Trial Success
- Whether AXS-05 can demonstrate superior efficacy and safety compared to bupropion and placebo in the SUMMIT trial.
- Regulatory Approval
- The timeline and potential hurdles for FDA approval of AXS-05 for smoking cessation.
- Market Potential
- The commercial viability of AXS-05 in a market where only 3-5% of smokers successfully quit without assistance.